June 11, 2021 – Pfizer Inc. (New York, NY) and BioNTech SE announced plans to provide the U.S. government at a not-for-profit price, 500 million doses of the companies’ COVID-19 vaccine – 200 million doses in 2021 and 300 million doses in the first half of 2022, to further support the multilateral efforts to address the surge of infection in many parts of the world and to help end the pandemic.
The U.S. government will, in turn, donate the Pfizer-BioNTech vaccine doses to low- and lower middle-income countries and organizations that support them.
As part of the plan, the United States will allocate the vaccine doses to 92 low- and lower middle-income countries and economies as defined by Gavi’s COVAX Advance Market Commitment (AMC) and the 55 member states of the African Union.
The U.S. government and the companies will work with COVAX to ensure these vaccines are delivered to the specified countries around the world in a way that is most efficient and equitable.
These doses are part of Pfizer and BioNTech’s previously announced pledge to provide two billion doses of the COVID-19 vaccine to low- and middle-income countries over the next 18 months.
Deliveries of the 200 million doses will begin in August 2021 and continue through the remainder of the year.
The 300 million doses for 2022 will be delivered between January and end of June 2022.
The U.S. government also has the option for additional doses in 2022.
The plan is to produce the doses being purchased by the U.S. government in Pfizer’s U.S. facilities. Those U.S.-based sites involved in the production of the COVID-19 vaccine include Kalamazoo, MI; Andover, MA; Chesterfield, MO; Groton, CT; and McPherson, KS.